Skip to main content
WAKAMOTO PHARMACEUTICAL CO.,LTD. logo

WAKAMOTO PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 4512 ISIN · JP3991200001 T Manufacturing
Open in API
Filings indexed 59 across all filing types
Latest filing 2019-02-13 Interim / Quarterly Rep…
Country JP Japan
Listing T 4512

About WAKAMOTO PHARMACEUTICAL CO.,LTD.

https://www.wakamoto-pharm.co.jp/englis…

WAKAMOTO PHARMACEUTICAL CO., LTD. is a company engaged in the research, development, production, and sale of pharmaceuticals. Its business encompasses both ethical (prescription) drugs and over-the-counter (OTC) products, as well as medical devices and health foods. The company specializes in therapeutic areas such as gastroenterology and is known as a pioneer in self-medication, with its flagship product being the nutrient-rich gastrointestinal remedy, "WAKAMOTO". The company actively manages a drug pipeline and engages in clinical trials to bring new therapeutic solutions to market.

Recent filings

Filing Released Lang Actions
四半期報告書－第124期第3四半期(2018/10/01－2018/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Wakamoto Pharmaceutical Co., Ltd., covering the third quarter of the 124th fiscal period (April 1, 2018, to December 31, 2018). It contains detailed financial statements, including the balance sheet and income statement, and is filed in accordance with the Financial Instruments and Exchange Act of Japan. As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial data, it is classified as an Interim/Quarterly Report. 9M 2019
2019-02-13 Japanese
四半期報告書－第124期第2四半期(2018/07/01－2018/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Wakamoto Pharmaceutical Co., Ltd., covering the second quarter of the 124th fiscal period (April 1, 2018, to September 30, 2018). It contains detailed financial statements, including the balance sheet and income statement, and is filed under the Financial Instruments and Exchange Act of Japan. This fits the definition of an Interim/Quarterly Report (IR). Q2 2019
2018-11-13 Japanese
四半期報告書－第124期第1四半期(2018/04/01－2018/06/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Wakamoto Pharmaceutical Co., Ltd. for the first quarter of the 124th fiscal period (April 1, 2018 to June 30, 2018). It contains detailed financial statements, including the balance sheet and income statement, and is prepared in accordance with the Financial Instruments and Exchange Act of Japan. As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial data, it is classified as an Interim/Quarterly Report. Q1 2019
2018-08-10 Japanese
有価証券報告書－第123期(平成29年4月1日－平成30年3月31日)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of the US 10-K. It contains comprehensive financial statements, business overviews, and historical data for the fiscal year ending March 31, 2018. It is a formal regulatory filing submitted to the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. FY 2018
2018-06-22 Japanese
四半期報告書－第123期第3四半期(2017/10/01－2017/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (第３四半期報告書) for Wakamoto Pharmaceutical Co., Ltd. It contains detailed financial statements (Balance Sheet, Income Statement), notes to the financial statements, and management analysis for the third quarter of the fiscal year. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2018
2018-02-13 Japanese
四半期報告書－第123期第2四半期(2017/07/01－2017/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Wakamoto Pharmaceutical Co., Ltd., covering the second quarter of the 123rd fiscal period (April 1, 2017, to September 30, 2017). It contains detailed financial statements, including the balance sheet, income statement, and cash flow statement, as required by the Financial Instruments and Exchange Act of Japan. Since it provides comprehensive financial data for an interim period, it is classified as an Interim/Quarterly Report. Q2 2018
2017-11-13 Japanese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.